This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City, NY; and Birmingham, AL. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Monogenic disease risks (MDRs)
Timeframe: 3 months after enrollment
Carrier status variants
Timeframe: 3 months after enrollment
MDR-associated phenotype
Timeframe: 3 months after enrollment and 1-year post-disclosure (15 months after enrollment)
Parenting stress, relationship dysfunction
Timeframe: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
Relationship satisfaction
Timeframe: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)
General anxiety
Timeframe: Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment)